KR930017895A - 아릴카보닐아미노알킬-디하이드로-옥소-피리딘, 이의 제조방법 및 이의 용도 - Google Patents
아릴카보닐아미노알킬-디하이드로-옥소-피리딘, 이의 제조방법 및 이의 용도 Download PDFInfo
- Publication number
- KR930017895A KR930017895A KR1019930002218A KR930002218A KR930017895A KR 930017895 A KR930017895 A KR 930017895A KR 1019930002218 A KR1019930002218 A KR 1019930002218A KR 930002218 A KR930002218 A KR 930002218A KR 930017895 A KR930017895 A KR 930017895A
- Authority
- KR
- South Korea
- Prior art keywords
- lower alkyl
- aryl
- formula
- compound
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Abstract
일반식(Ⅰ)의 아릴카보닐아미노알킬-디하이드로-옥소-피리딘이 기술되어 있다.
상기식에서, 아릴은 방향족 또는 헤테로방향족 계이고, n은 0내지 5이며, R 및 R(1)은 수소 또는 저급알킬이고, W는 수소, (헤테로)-(아릴)-저급알킬이며, Z는 수소, CH2OR(2), CHO, (CO)OR(2), (CO)NR(2)2이다.
상기 일반식(Ⅰ)의 화합물의 제조방법 또한 기술되어 있다.
일반식(Ⅰ)의 화합물은 예를 들면 고혈압 치료를 위한 심장 혈관계 질환의 치료, 심기능부진의 치료 또는 앙기나와 같은 관상계에서 혈류 장애의 치료시 적합하다. 또한, 뇌 및 관상계 혈류 장애에도 유리하게 영향을 미칠 수 있다. 더우기, 일반식(Ⅰ)의 화합물은 자궁, 기관지, 장 및 담즙계와 같은 평활근 기관, 진경의 의미로서 요로(뇨관, 방광 및 요도)에 영향을 미칠 수 있다. 따라서, 이들은 또한 상기 기관의 경축과 연관된 질환, 예를 들면, 임신중 조산, 뇨관 또는 간산통, 기도 폐쇄 질환(예:천식), 장운동의 장애(예: 흥분성 결장 또는 방광실금)의 치료를 위해 적합하다. 추가로, 일반식(Ⅰ)의 화합물은 간질치료시 경련 발현 억제제 및 대머리 치료시 모발 성장 유도제로서 공급될 수 있다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (10)
- 일반식(Ⅰ)의 아릴카보닐아미노알킬-디하이드로-옥소-피리딘 및 이의 기하학적 이성체, 또는 광학적 대장체.상기식에서, 아릴은 1내지 2개의 동일하거나 상이한 할로겐, 저급알킬, 알콕시, 또는 트리플루오로메틸 라디칼에 의해 치환되거나 비치환된 방향족 또는 헤테로방향족계이고, n은 0내지 5이며, R 및 R(1)은 독립적으로 각각의 탄소에 대해서 (n이 0내지 5일경우), 독립적으로 수소, 또는 저급알킬이며, W는 수소, 저급알킬, 아릴 저급알킬, 또는 헤테로아릴저급알킬이고, Z는 수소, CH2OR(2), CHO, (CO)OR(2), (CO)NR(2)2〔여기서, R(2)는 독립적으로 수소, 저급알킬, 사이클로알킬, 비사이클로알킬, 아릴, 아릴저급알킬, 헤테로아릴, 또는 헤테로아릴저급알킬이다〕이다.
- 제1항에 있어서, 아릴이 방향족 및 헤테로방향족 계이고, n이 0,2 및 3이며, Z가 수소, (CO)OR(2), (CO)NR(2)2〔여기서, R(2)는 독립적으로 수소, 저급알킬, 및 아릴저급알킬이다〕인 일반식(I)의 화합물.
- 제2항에 있어서, 아릴이 피리디닐 계이고, n이 0,2 및 3이며, Z가 수소, (CO)OR(2), (CO)NR(2)2〔여기서, R(2)는 독립적으로 수소, 저급알킬 및 아릴저급알킬이다〕인 일반식(I)의 화합물.
- 제2항에 있어서, 아릴이 피리디닐 계이고, n이 2이며, Z가 (CO)R(2)〔여기서, R(2)는 저급알킬이다〕인 일반식(I)의 화합물.
- 제2항에 있어서, 아릴이 퀴놀리닐 계이고, n이 2이며, Z가 (CO)R(2)〔여기서, R(2)는 저급알킬이다〕인 일반식(I)의 화합물.
- 제2항에 있어서, 아릴이 페닐 계이고, n이 2이며, Z가 (CO)R(2)〔여기서, R(2)는 저급알킬이다〕인 일반식(I)의 화합물.
- 제1항에 잇어서, 1,6-디하이드로-1-〔2-(2-피리딜닐카보닐 아미노)에틸〕-6-옥소-3-피리딘카복실산 메틸 에스테르, 1,6-디하이드로-6-옥소-1-〔2-(2-피라지닐카보닐아미노)에틸〕-3-피리딘카복실산 메틸 에스테르, 1,6-디하이드로-6-옥소-1-〔2-(3-퀴놀리닐카보닐아미노)에틸〕-3-피리딘카복실산 메틸 에스테르, 1-〔2-벤조일아미노에틸〕-1,6-디하이드로-6-옥소-3-피리딘카복실산 메틸 에스테르로 이루어진 그룹으로부터 선택된 일반식(I)의 화합물.
- a) 일반식(Ⅳ)의 화합물을 2-옥소-2H-피란-5-카복실산 메틸 에스테르(Ⅴ)와 반응시켜 Z가 3-CO2CH3인 일반식(I)의 화합물을 수득하거나, b) 일반식(Ⅵ)의 화합물을 아릴카복실산 클로라이드(Ⅶ) 또는 아릴 카복실산(Ⅷ)과 반응시키거나, c) 일반식(Ⅸ)의 화합물을 하이드록시피리딘(Ⅹ)와 반응시켜 일반식(XI)의 화합물을 수득하고, 계속해서 탈보호시켜 일반식(Ⅵ)의 화합물을 수득하고 이를 최종 단계에서 일반식(Ⅶ)의 화합물 및 일반식(Ⅷ)의 화합물과 반응시킴을 특징으로 하여, 제1항에 청구된 바와 같은 일반식(I)의 화합물을 제조하는 방법.상기식에서, 아릴은 1내지 2개의 동일하거나 상이한 할로겐, 저급알킬, 알콕시, 또는 트리플루오로메틸 라디칼에 의해 치환되거나 비치환된 방향족 또는 헤테로방향족계이고, n은 0내지 5이며, R 및 R(1)은 독립적으로 각각의 탄소에 대해서 (n은 0내지 5일경우), 독립적으로 수소, 또는 저급알킬이며, W는 수소, 저급알킬, 아릴저급알킬, 또는 헤테로아릴저급알킬이고, Z는 수소, CH2OR(2), CHO, (CO)OR(2), (CO)NR(2)2〔여기서, R(2)는 독립적으로 수소, 저급알킬, 사이클로알킬, 비사이클로알킬, 아릴, 아릴저급알킬, 헤테로아릴, 또는 헤테로아릴저급알킬이다〕인데, 일반식(Ⅵ)에서 Z는 3-CO2CH3이며, Hal은 염소 또는 브롬이다.
- 고혈압, 협심증, 심기능부진, 말초혈류장애, 장운동장애, 조기 유산, 기도폐쇄, 뇨관 또는 답즙관의 폐쇄 또는 경련상태 치료용의 약제를 제조하기 위한 제1항에 청구된 바와 같은 일반식(I)의 화합물의 용도.
- 제1항에 청구된 바와 같은 일반식(Ⅰ)의 화합물을 유효함량을 포함하는 고혈압, 협심증, 심기능부진, 말초혈류장애, 장운동장애, 조산, 기도폐쇄, 뇨관 또는 답즙관의 폐쇄 또는 경련상태 치료용의 약제.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP92102828 | 1992-02-20 | ||
DE92-102828.8 | 1992-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR930017895A true KR930017895A (ko) | 1993-09-20 |
Family
ID=8209352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019930002218A KR930017895A (ko) | 1992-02-20 | 1993-02-18 | 아릴카보닐아미노알킬-디하이드로-옥소-피리딘, 이의 제조방법 및 이의 용도 |
Country Status (17)
Country | Link |
---|---|
US (1) | US5360808A (ko) |
EP (1) | EP0556738B1 (ko) |
JP (1) | JPH069560A (ko) |
KR (1) | KR930017895A (ko) |
CN (1) | CN1075480A (ko) |
AT (1) | ATE122659T1 (ko) |
AU (1) | AU3375993A (ko) |
CA (1) | CA2089955A1 (ko) |
CZ (1) | CZ403592A3 (ko) |
DE (1) | DE69300152D1 (ko) |
FI (1) | FI930716A (ko) |
HU (1) | HU9300463D0 (ko) |
IL (1) | IL104781A0 (ko) |
MA (1) | MA22806A1 (ko) |
MX (1) | MX9300915A (ko) |
NO (1) | NO930594L (ko) |
ZA (1) | ZA931185B (ko) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020052295A1 (en) * | 1999-12-21 | 2002-05-02 | Hegde Shridhar G. | Diacyl derivatives of propylene diamine having herbicidal activity |
DE10205219A1 (de) * | 2002-02-08 | 2003-08-21 | Bayer Ag | Chinoxalinone und ihre Verwendung |
US6869966B2 (en) * | 2002-09-30 | 2005-03-22 | Banyu Pharmaceutical Co., Ltd. | N-substituted-2-oxodihydropyridine derivatives |
US20040127129A1 (en) * | 2002-12-31 | 2004-07-01 | Shuiyuan Luo | Grooved-shape monofilaments and the fabrics made thereof |
WO2007008963A1 (en) * | 2005-07-13 | 2007-01-18 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
EP2114898A2 (en) * | 2007-02-16 | 2009-11-11 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
US8153808B2 (en) | 2008-12-23 | 2012-04-10 | Roche Palo Alto Llc | Dihydropyridone amides as P2X7 modulators |
WO2010072599A1 (en) | 2008-12-23 | 2010-07-01 | F. Hoffmann-La Roche Ag | Dihydropyridone ureas as p2x7 modulators |
CA2745952A1 (en) | 2008-12-23 | 2010-07-01 | F.Hoffmann-La Roche Ag | Dihydropyridone amides as p2x7 modulators |
KR101381074B1 (ko) | 2008-12-23 | 2014-04-11 | 에프. 호프만-라 로슈 아게 | P2x7 조절제로서의 디히드로피리돈 아미드 |
SG172785A1 (en) | 2008-12-23 | 2011-08-29 | Hoffmann La Roche | Dihydropyridone amides as p2x7 modulators |
WO2011023696A1 (en) | 2009-08-26 | 2011-03-03 | Nycomed Gmbh | Methylpyrrolopyridinecarboxamides |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2637477A1 (de) * | 1976-08-20 | 1978-02-23 | Hoechst Ag | Dihydro-oxo-nicotinsaeuren und verfahren zu ihrer herstellung |
US4297360A (en) * | 1980-03-28 | 1981-10-27 | Sterling Drug Inc. | 5-(Pyridinyl)pyridine-2,3-diamines, preparation thereof and their cardiotonic use |
NZ195564A (en) * | 1979-11-26 | 1983-09-30 | Sterling Drug Inc | 5-pyridinyl-2(1h)-pyridinones pharmaceutical compositions intermediate pyridine compounds |
IT8367883A0 (it) * | 1982-08-23 | 1983-08-22 | Rorer Int Overseas | Composti cardiotonici del 2 piridone 5 biciclico eteroaril sostituito e relative composizioni farmaceutiche |
GB8809481D0 (en) * | 1988-04-21 | 1988-05-25 | Smith Kline French Lab | Chemical compounds |
-
1992
- 1992-12-31 CZ CS924035A patent/CZ403592A3/cs unknown
-
1993
- 1993-02-12 EP EP93102220A patent/EP0556738B1/en not_active Expired - Lifetime
- 1993-02-12 DE DE69300152T patent/DE69300152D1/de not_active Expired - Lifetime
- 1993-02-12 AT AT93102220T patent/ATE122659T1/de not_active IP Right Cessation
- 1993-02-18 US US08/019,296 patent/US5360808A/en not_active Expired - Fee Related
- 1993-02-18 FI FI930716A patent/FI930716A/fi not_active Application Discontinuation
- 1993-02-18 KR KR1019930002218A patent/KR930017895A/ko not_active Application Discontinuation
- 1993-02-18 IL IL104781A patent/IL104781A0/xx unknown
- 1993-02-19 ZA ZA931185A patent/ZA931185B/xx unknown
- 1993-02-19 NO NO93930594A patent/NO930594L/no unknown
- 1993-02-19 MA MA23099A patent/MA22806A1/fr unknown
- 1993-02-19 CN CN93101816A patent/CN1075480A/zh active Pending
- 1993-02-19 AU AU33759/93A patent/AU3375993A/en not_active Abandoned
- 1993-02-19 JP JP5029515A patent/JPH069560A/ja active Pending
- 1993-02-19 MX MX9300915A patent/MX9300915A/es unknown
- 1993-02-19 CA CA002089955A patent/CA2089955A1/en not_active Abandoned
- 1993-02-19 HU HU9300463A patent/HU9300463D0/hu unknown
Also Published As
Publication number | Publication date |
---|---|
DE69300152D1 (de) | 1995-06-22 |
EP0556738B1 (en) | 1995-05-17 |
EP0556738A1 (en) | 1993-08-25 |
MX9300915A (es) | 1993-09-01 |
ZA931185B (en) | 1993-09-16 |
CA2089955A1 (en) | 1993-08-21 |
NO930594D0 (no) | 1993-02-19 |
CZ403592A3 (en) | 1993-12-15 |
AU3375993A (en) | 1993-08-26 |
US5360808A (en) | 1994-11-01 |
IL104781A0 (en) | 1993-06-10 |
FI930716A (fi) | 1993-08-21 |
NO930594L (no) | 1993-08-23 |
JPH069560A (ja) | 1994-01-18 |
ATE122659T1 (de) | 1995-06-15 |
FI930716A0 (fi) | 1993-02-18 |
HU9300463D0 (en) | 1993-05-28 |
CN1075480A (zh) | 1993-08-25 |
MA22806A1 (fr) | 1993-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR930017895A (ko) | 아릴카보닐아미노알킬-디하이드로-옥소-피리딘, 이의 제조방법 및 이의 용도 | |
EP0493608B1 (en) | Quinolonecarboxylic acid derivative | |
US5254565A (en) | Quinoline derivatives, their production and use | |
JPH05294954A (ja) | 新規ベンゾピラン誘導体 | |
KR19990028757A (ko) | 벤조[g]퀴놀린 유도체 | |
EP0636619A1 (en) | Tricyclic heterocyclic compound | |
KR890001147B1 (ko) | 2-치환 또는 비치환된 아미노카르보닐 옥시알킬-1,4-디히드로피리딘류의 제조방법 | |
US20050245750A1 (en) | Process for preparing 1,3-benzodioxole-2-spirocycloalkane derivative | |
RU2155765C2 (ru) | Производные 1,4-дигидропиридина с циклическим мостиком в положениях 1,2 в форме смеси их изомеров | |
JP3196383B2 (ja) | スクアリリウム系化合物 | |
CA2026974C (en) | 3-aroyl-2-oxindole-1-carboximides | |
JPH037259A (ja) | Acat阻害剤、キノリン誘導体及びその製造法 | |
US4290954A (en) | Tetrahydroxanthone derivatives | |
JPS61268651A (ja) | フエニル酢酸誘導体およびその製造法 | |
CA2113349C (en) | Method of producing a quinolonecarboxylic acid derivative | |
EP0595467B1 (en) | Process for preparing antifolate 4-hydroxypyrrolo 2,3-d pyrimidine derivatives | |
JP4907486B2 (ja) | グリニャール試薬の製法 | |
JP3535565B2 (ja) | ベンゾピラン誘導体 | |
KR0159511B1 (ko) | 신규의 퀴놀린유도체 및 그 제조방법 | |
KR860000671B1 (ko) | 퀴놀린 카르복실산의 피페라지닐 유도체의 제조 방법 | |
WO1993025532A1 (en) | Carboxylic acid derivative and production thereof | |
JPH10158249A (ja) | キナゾリノン誘導体 | |
HU192651B (en) | Process for preparing optically active derivatives of 1-/3-chloro-propyl/3-oxo-1,2,3,5,6,11b-hexahydro-indolysino/8,7-b/indole | |
JPS58113185A (ja) | 新規ベンゾチアゼピン誘導体およびその製造法 | |
JPH0213663B2 (ko) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |